ConductScience.org, home

Paper · 30874331

The Sprouty/Spred family as tumor suppressors: Coming of age.

Kawazoe T and 1 other. Cancer Sci, 2019. Cited by 53 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The Sprouty/Spred family as tumor suppressors: Coming of age. Papers, record 30874331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30874331

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Sprouty/Spred family as tumor suppressors: Coming of age.
PubMed
Journal
Cancer Sci
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
53
iCite
Relative citation ratio, by iCite
2.15
iCite
Revised in PubMed
2021-01-09
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kawazoe TTetsurohttps://orcid.org/0000-0002-5351-5089
2Taniguchi KKojihttps://orcid.org/0000-0002-8091-6005

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Membrane ProteinsMajor topic
NeoplasmsMajor topic
Disease Progression
Gene Expression Regulation, Neoplastic
Humans
MAP Kinase Signaling System
Mitogen-Activated Protein Kinases
Multigene Family
ras Proteins

Source PubMed

Grants33

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
JP18gm6210008Japan Agency for Medical Research and DevelopmentPubMed
JP19gm6210008Japan Agency for Medical Research and DevelopmentPubMed
JP15K21775Japan Society for the Promotion of SciencePubMed
"Kibou Projects" Startup Support for Young Researchers in ImmunologyPubMed
Astellas Foundation for Research on Metabolic DisordersPubMed
SENSHIN Medical Research FoundationPubMed
Bristol-Myers SquibbPubMed
SGH FoundationPubMed
MSD Life Science FoundationPubMed
Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical CarePubMed

1 to 10 of 33Source PubMed

See all 33 grants

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References87

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125,630,587Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.Int J Cancer2015https://conductscience.org/library/papers/25630587PubMed
230,745,814A Pilot Study of Aberrant CpG Island Hypermethylation of SPRED1 in Acute Myeloloid Leukemia.Int J Med Sci2019https://conductscience.org/library/papers/30745814PubMed
316,489,004Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.Cancer Res2006https://conductscience.org/library/papers/16489004PubMed
427,621,461SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling.Proc Natl Acad Sci U S A2016https://conductscience.org/library/papers/27621461PubMed
525,973,316Tumor-specifically hypoxia-induced therapy of SPRY1/2 displayed differential therapeutic efficacy for melanoma.Am J Cancer Res2015https://conductscience.org/library/papers/25973316PubMed
628,223,824miR182 activates the Ras-MEK-ERK pathway in human oral cavity squamous cell carcinoma by suppressing RASA1 and SPRED1.Onco Targets Ther2017https://conductscience.org/library/papers/28223824PubMed
725,633,921Correlation between microRNA‑21 and sprouty homolog 2 gene expression in multiple myeloma.Mol Med Rep2015https://conductscience.org/library/papers/25633921PubMed
824,932,220The expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cells.J Ovarian Res2014https://conductscience.org/library/papers/24932220PubMed
926,434,583Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial-mesenchymal transition.Oncogene2016https://conductscience.org/library/papers/26434583PubMed
1026,157,547Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells.Biomol Ther (Seoul)2015https://conductscience.org/library/papers/26157547PubMed

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.

PMIDTitleJournalYearIn PapersSource
41,929,490Intact lymph node homing and CD8+ T-cell priming abilities of Sprouty2-deficient dendritic cells.Front Immunol2026https://conductscience.org/library/papers/41929490PubMed
41,516,252Sprouty in Tumors of the Nervous System.Int J Mol Sci2025https://conductscience.org/library/papers/41516252PubMed
41,155,983Targeting Kinase Suppressor of Ras 1 (KSR1) for Cancer Therapy.Pharmaceutics2025https://conductscience.org/library/papers/41155983PubMed
40,948,827Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through SPRED1.Transl Lung Cancer Res2025https://conductscience.org/library/papers/40948827PubMed
40,915,975Poricoic Acid A attenuated TGF-β1-induced epithelial-mesenchymal transition in renal tubular epithelial cells through SPRY2/ERK signaling pathway.Korean J Physiol Pharmacol2025https://conductscience.org/library/papers/40915975PubMed
40,806,483The Lysine at Position 177 Is Essential to Limit the Inhibitory Capacities of Sprouty4 Protein in Normal and Cancer-Derived Cells.Int J Mol Sci2025https://conductscience.org/library/papers/40806483PubMed
40,121,554BAMBI integrates biostatistical and artificial intelligence methods to improve RNA biomarker discovery.Brief Bioinform2025https://conductscience.org/library/papers/40121554PubMed
40,023,001SPRY1 regulates macrophage M1 polarization in skin aging and melanoma prognosis.Transl Oncol2025https://conductscience.org/library/papers/40023001PubMed
39,682,716Sprouty2 Regulates Endocytosis and Degradation of Fibroblast Growth Factor Receptor 1 in Glioblastoma Cells.Cells2024https://conductscience.org/library/papers/39682716PubMed
39,227,612SPRED3 regulates the NF-κB signaling pathway in thyroid cancer and promotes the proliferation.Sci Rep2024https://conductscience.org/library/papers/39227612PubMed

1 to 10 of 39

See all 39 cited by

Genes61

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30874331

GET https://conductscience.org/api/papers/v1/30874331/grants?page=2